IVDR Transition Guide for Small Labs & Startups

The In Vitro Diagnostic Regulation (IVDR, EU 2017/746) is fundamentally reshaping how diagnostic products reach the European market. For small laboratories, IVD startups, and research teams developing companion diagnostics, the transition from the old IVD Directive (98/79/EC) represents both a massive compliance challenge and a strategic inflection point. With the Class C deadline on May 26, 2026, the time to act is now.

IVDR Transition Timeline

The IVDR entered into force on May 26, 2017, with a five-year transition period that was subsequently extended by Regulation (EU) 2022/112. The staggered deadlines are based on device risk class:

• May 26, 2022: IVDR applies in full. New devices without IVDD certificates must comply immediately.
• May 26, 2025: Class D devices (highest risk, e.g., blood grouping, HIV tests) — transition deadline passed.
• May 26, 2026: Class C devices (e.g., companion diagnostics, self-testing glucose monitors, HLA typing) must comply.
• May 26, 2027: Class B and Class A sterile devices must comply.
• May 26, 2028–2029: Remaining Class A (self-declared) devices complete the transition.

Key point: If your device had a valid IVDD certificate or self-declaration before May 26, 2022, you benefit from the extended transition. If it did not, IVDR applies now regardless of risk class.

The Notified Body Bottleneck

Under the old IVDD, roughly 80% of IVDs were self-declared (no Notified Body involvement). Under IVDR, that ratio is essentially reversed: approximately 80% of IVDs now require Notified Body certification. This represents a seismic shift in demand for NB capacity.

As of early 2026, only approximately 19 Notified Bodies have been designated for IVDR — compared to over 50 for the Medical Device Regulation (MDR). This creates a severe capacity bottleneck, particularly for Class C and D devices that require the most intensive reviews.

Practical implications for small labs and startups:

• Engage early: Notified Bodies are prioritizing existing clients and larger manufacturers. New applicants may face 12–18 month wait times just to begin the review process.
• Prepare a complete dossier: NBs are rejecting incomplete applications outright. Submitting a well-prepared technical documentation package is essential to avoiding delays.
• Consider NB scope carefully: Not all designated NBs cover all device classes or technology areas. Verify that your chosen NB is designated for your specific product type.
• Budget for NB fees: IVDR NB fees are significantly higher than under IVDD. Expect €30K–€150K+ for the initial certification process depending on device class and complexity.

Laboratory Developed Tests (LDTs) Under IVDR

One of the most significant changes under IVDR is the regulation of Laboratory Developed Tests (LDTs) — tests manufactured and used within a single health institution. Under the old IVDD, LDTs were effectively unregulated at the EU level. IVDR changes this through Article 5(5).

Article 5(5) provides a narrow exemption for health institutions manufacturing IVDs in-house, but only if all of the following conditions are met:

1. No equivalent CE-marked device is available on the market (or the available device does not meet the specific needs of the target patient group).
2. The health institution does not transfer the device to another legal entity.
3. Manufacture and use occur under appropriate quality management systems.
4. The health institution justifies the manufacture in its documentation and makes this available to the competent authority on request.
5. The health institution drafts a declaration that is made publicly available, including the name and address of the institution and an overview of the devices produced.
6. The devices meet the general safety and performance requirements of Annex I (where applicable).

Important: The “no equivalent CE-marked device available” condition is strictly interpreted. If a CE-marked alternative exists that could meet the clinical need, the exemption does not apply — even if the lab prefers its own test.

Performance Evaluation Requirements

IVDR requires a comprehensive performance evaluation for every IVD, structured around three pillars:

• Scientific validity: The association between the analyte and a clinical condition or physiological state must be well-established, supported by published literature and recognized standards.
• Analytical performance: Sensitivity, specificity, accuracy, precision, reproducibility, detection limits, measuring range, linearity, cross-reactivity, and interference. This must be demonstrated through analytical performance studies.
• Clinical performance: Diagnostic sensitivity, diagnostic specificity, positive/negative predictive values, likelihood ratios, and expected values in normal and affected populations. Clinical performance studies are required for most devices.

For small labs, the clinical performance requirement is often the most challenging. You need access to well-characterized clinical samples, and the study must be designed with appropriate statistical power. Multi-site studies may be needed for higher-class devices.

Cost and Timeline Estimates for Small Labs

Based on industry data and experience, here are realistic cost and timeline ranges for small laboratories and startups seeking IVDR compliance:

• Total compliance cost: $200K–$800K depending on device class, complexity, and whether clinical performance studies are needed.
• Timeline to certification: 18–36 months from project initiation to CE marking, including NB engagement time.
• Technical documentation preparation: $50K–$200K for regulatory consulting and documentation writing.
• Performance evaluation studies: $30K–$300K depending on analytical and clinical study scope.
• QMS establishment/upgrade: $20K–$80K for ISO 13485 certification or upgrade to IVDR-compliant systems.
• Notified Body fees: $30K–$150K+ for initial certification review and audit.

Practical Compliance Checklist

Use this checklist to plan your IVDR transition:

1. Conduct a gap analysis — Compare your current documentation and processes against IVDR requirements. Identify what you have, what needs updating, and what needs to be created from scratch.
2. Classify your devices under IVDR — Use the risk-based classification rules in Annex VIII. Many devices will move up in class compared to IVDD.
3. Engage a Notified Body early — Submit a pre-submission inquiry to your preferred NB. Understand their timeline, scope, and documentation expectations.
4. Build your performance evaluation plan — Define the analytical and clinical performance studies needed. Secure access to clinical samples and plan multi-site protocols if required.
5. Prepare technical documentation — Follow Annex II and III requirements. Include device description, risk management, performance evaluation, labelling, and post-market surveillance plan.
6. Establish or upgrade your QMS — Ensure ISO 13485 compliance with IVDR-specific requirements for production, traceability, and vigilance.
7. Register in EUDAMED — Register your economic operator information and device data as the relevant EUDAMED modules become available.
8. Plan post-market surveillance — Develop a PMS plan and PMPF (Post-Market Performance Follow-up) plan proportionate to your device class.